Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection.

Herbst DA Jr, Reddy KR.

Expert Opin Investig Drugs. 2013 Apr;22(4):527-36. doi: 10.1517/13543784.2013.775246. Review.

PMID:
23448131
2.

Sofosbuvir (Sovaldi°). Active against hepatitis C virus, but evaluation is incomplete .

[No authors listed]

Prescrire Int. 2015 Jan;24(156):5-10.

PMID:
25734194
3.

Sofosbuvir: a review of its use in patients with chronic hepatitis C.

Keating GM.

Drugs. 2014 Jul;74(10):1127-46. doi: 10.1007/s40265-014-0247-z. Review.

PMID:
24958336
4.

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators..

N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366.

5.

A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir.

Gentile I, Borgia F, Buonomo AR, Castaldo G, Borgia G.

Curr Med Chem. 2013;20(30):3733-42. Review.

PMID:
23848533
6.

Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection.

Koff RS.

Aliment Pharmacol Ther. 2014 Mar;39(5):478-87. doi: 10.1111/apt.12601. Review. Erratum in: Aliment Pharmacol Ther. 2014 Apr;39(8):904.

7.

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR; POSITRON Study.; FUSION Study..

N Engl J Med. 2013 May 16;368(20):1867-77. doi: 10.1056/NEJMoa1214854.

8.

Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1.

Kumari R, Nguyen MH.

Expert Opin Pharmacother. 2015 Apr;16(5):739-48. doi: 10.1517/14656566.2015.1013938. Review.

PMID:
25676581
9.

Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.

Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Subramanian GM, Symonds WT, McHutchison JG, Pang PS.

Gastroenterology. 2014 Mar;146(3):736-743.e1. doi: 10.1053/j.gastro.2013.11.007.

PMID:
24262278
10.

Hepatitis C therapy with HCV NS5B polymerase inhibitors.

Soriano V, Vispo E, de Mendoza C, Labarga P, Fernandez-Montero JV, Poveda E, Treviño A, Barreiro P.

Expert Opin Pharmacother. 2013 Jun;14(9):1161-70. doi: 10.1517/14656566.2013.795543. Review.

PMID:
23621117
11.

Hepatitis C virus therapy in the direct acting antiviral era.

Shiffman ML.

Curr Opin Gastroenterol. 2014 May;30(3):217-22. doi: 10.1097/MOG.0000000000000062. Review.

PMID:
24625897
12.

Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus.

Summers BB, Beavers JW, Klibanov OM.

J Pharm Pharmacol. 2014 Dec;66(12):1653-66. doi: 10.1111/jphp.12294. Review.

PMID:
25175944
13.

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; ION-1 Investigators..

N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454.

14.

Sofosbuvir for the treatment of chronic hepatitis C virus infection.

Temesgen Z, Talwani R, Rizza SA.

Drugs Today (Barc). 2014 Jun;50(6):421-34. doi: 10.1358/dot.2014.50.6.2141371. Review.

PMID:
24983590
15.

Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.

D'Ambrosio R, Aghemo A, Colombo M.

Expert Opin Drug Saf. 2015 Mar;14(3):473-84. doi: 10.1517/14740338.2015.1009035. Review.

PMID:
25645644
16.

The rapid evolution of treatment strategies for hepatitis C.

Muir AJ.

Am J Gastroenterol. 2014 May;109(5):628-35; quiz 636. doi: 10.1038/ajg.2014.66. Review.

PMID:
24732866
17.

Sofosbuvir-based interferon-free therapy for patients with HCV infection.

Asselah T.

J Hepatol. 2013 Dec;59(6):1342-5. doi: 10.1016/j.jhep.2013.07.023. No abstract available.

18.

Sofosbuvir (Sovaldi) for the treatment of hepatitis C.

Lam B, Henry L, Younossi Z.

Expert Rev Clin Pharmacol. 2014 Sep;7(5):555-66. doi: 10.1586/17512433.2014.928196. Review.

PMID:
24918162
19.

Sofosbuvir: first global approval.

Keating GM, Vaidya A.

Drugs. 2014 Feb;74(2):273-82. doi: 10.1007/s40265-014-0179-7. Review.

PMID:
24442794
20.

Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?

Sofia MJ.

Antiviral Res. 2014 Jul;107:119-24. doi: 10.1016/j.antiviral.2014.04.008.

PMID:
24792751

Supplemental Content

Support Center